NewswireToday - /newswire/ -
Monrovia, CA, United States, 2013/01/24 - Lin Xu, Principle Scientist at Biogen Idec to Present at the 6th Imaging in Drug Discovery and Development Conference, to be held onMay 8-10, 2013 in Boston, MA - GTCbio.com.
Lin Xu, Principle Scientist at Biogen Idec, to present “Imaging Drug And Metabolites In Target Tissue Using Ambient Surface Sampling Mass Spectrometry” at the 6th Imaging in Drug Discovery and Development Conference to be held in Boston, MA on May 8-10, 2013 by GTC.
Understanding the tissue distribution of drug entities is an essential step in drug development. Localization of the drug at the target site enhances confidence in the mechanism of action. It can help to demonstrate specific target organ localization and to support claims regarding the duration of action.
In order to understand drug distribution at the target tissue in a simple and quick approach, Dr. Xu and his team applied recently developed MS based surface sampling techniques, desorption electrospray ionization (DESI) and liquid extraction surface analysis (LESA). The advantages of these techniques over autoradiography and LC-MS were successfully demonstrated in the analysis of the distribution of drug A and its metabolites in rat brain tissue. The dynamic distribution of the drug candidate was found to differ in the white and gray matter of the brain (target tissue). The distribution of the major metabolites was also different; the oxidized metabolite displayed a homogenous distribution while the desaturated metabolite tracked with the parent drug.
Dr. Lin Xu is a Principle Scientist in the Drug Metabolism and Pharmacokinetic Department at Biogen Idec. He earned his Bachelor of Science in Chemistry at Nankai University in China and Ph.D. in Organic Chemistry at the University of British Columbia. In his postdoctoral fellowship at University of Rochester Medical Center, Dr. Xu identifed N-EtFOSE metabolites and elucidated N-EtFOSE metabolic pathway in vitro and vivo using LC/MS/MS by collaborating with the toxicological department at 3M Corporation. After he joined Merck, Dr. Xu participated as a DMPK representative in drug discovery teams to perform and design drug metabolism, pharmacokinetic studies, and biotransformation study and PK/PD modeling. In his current role at Biogen Idec, Dr. Xu manages in vitro and in vivo biotransformation studies to support drug discovery and drug development for regulatory agency filings. He has contributed over 20 publications to the drug metabolism and toxicology society.
GTC’s 6th Imaging in Drug Discovery and Development Conference brings together experts from academia, government, and industry from the National Cancer Institute, Stanford University, City of Hope and the Beckman Research Institute, Yale School of Medicine, Pfizer, Biogen Idec, PerkinElmer, Eisai, Columbia University, Roche, Sanofi-Aventis, Janssen, and many more to discuss the latest developments and applications in imaging to further advance their molecular imaging projects on drug discovery and development.
This conference is also part of the Drug Discovery Summit 2013, which consists of this track and three other tracks:
7th Drug Design and Medicinal Chemistry
3rd Epigenetics in Drug Discovery
Orphan Drugs Research and Commercialization